Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedSep 25, 2025
DataAggregated Company Financials
Companies546
  • 7D1.3%
  • 3M9.6%
  • 1Y-4.1%
  • YTD7.2%

In the last week, the Biotech industry is up 1.3%, with Amgen leading the way with a 1.6% gain. However, the industry is down 4.1% over the past year. Looking forward, earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 25 Sep 2025US$1.1tUS$163.5b-US$18,318,414,671.6116.5x-59.2x6.6x
Sat, 23 Aug 2025US$1.1tUS$163.6b-US$18,600,438,658.1415.1x-57.7x6.6x
Mon, 21 Jul 2025US$961.3bUS$155.2b-US$23,259,963,048.3216.5x-41.3x6.2x
Wed, 18 Jun 2025US$940.7bUS$155.9b-US$23,954,335,834.0417.1x-39.3x6x
Fri, 16 May 2025US$863.7bUS$155.9b-US$24,603,386,779.2214.7x-35.1x5.5x
Sun, 13 Apr 2025US$740.4bUS$119.2b-US$36,465,001,079.3419.8x-20.3x6.2x
Tue, 11 Mar 2025US$845.2bUS$118.7b-US$37,516,362,615.2518.1x-22.5x7.1x
Thu, 06 Feb 2025US$852.4bUS$117.2b-US$30,787,020,617.0917.5x-27.7x7.3x
Sat, 04 Jan 2025US$971.4bUS$149.6b-US$26,354,792,434.1217x-36.9x6.5x
Mon, 02 Dec 2024US$1.0tUS$150.0b-US$26,595,044,865.3416.4x-39.2x6.9x
Wed, 30 Oct 2024US$898.1bUS$113.4b-US$36,099,862,624.1320.1x-24.9x7.9x
Fri, 27 Sep 2024US$885.6bUS$113.2b-US$36,051,039,342.9521.4x-24.6x7.8x
Sun, 25 Aug 2024US$908.6bUS$113.2b-US$35,874,993,723.2123.6x-25.3x8x
Tue, 23 Jul 2024US$1.2tUS$164.5b-US$28,074,139,763.4429.1x-42.5x7.3x
Thu, 20 Jun 2024US$1.1tUS$164.4b-US$27,969,500,563.9827.2x-40.6x6.9x
Sat, 18 May 2024US$1.1tUS$164.6b-US$26,831,179,712.6623.9x-42.7x7x
Mon, 15 Apr 2024US$1.1tUS$164.3b-US$23,399,427,407.8721.1x-46.9x6.7x
Wed, 13 Mar 2024US$1.2tUS$167.3b-US$22,031,216,768.7918.8x-54.1x7.1x
Fri, 09 Feb 2024US$1.2tUS$169.3b-US$26,196,624,627.9119.6x-44x6.8x
Sun, 07 Jan 2024US$1.4tUS$204.8b-US$22,501,061,722.0020.5x-63.1x6.9x
Tue, 05 Dec 2023US$1.3tUS$204.7b-US$22,047,091,184.0019x-57.3x6.2x
Thu, 02 Nov 2023US$1.2tUS$207.6b-US$15,463,681,135.0016.9x-77.5x5.8x
Sat, 30 Sep 2023US$1.3tUS$207.4b-US$12,733,898,979.0017.1x-99.6x6.1x
Mon, 28 Aug 2023US$1.3tUS$207.6b-US$12,455,656,838.0017.5x-102.5x6.1x
Wed, 26 Jul 2023US$1.1tUS$186.4b-US$16,520,100,805.0014.4x-68.6x6.1x
Fri, 23 Jun 2023US$1.1tUS$186.3b-US$16,130,651,001.0013.8x-71.1x6.2x
Sun, 21 May 2023US$1.2tUS$186.0b-US$15,897,732,960.0012.9x-72.5x6.2x
Tue, 18 Apr 2023US$1.2tUS$198.4b-US$3,286,383,305.0013.9x-359.8x6x
Thu, 16 Mar 2023US$1.1tUS$199.2b-US$4,736,811,399.0013.1x-237.9x5.7x
Sat, 11 Feb 2023US$1.2tUS$202.7b-US$201,937,721.0016.4x-5723.2x5.7x
Mon, 09 Jan 2023US$1.2tUS$203.3bUS$1.6b14.7x735.2x5.8x
Wed, 07 Dec 2022US$1.1tUS$202.7bUS$1.4b14.8x802.1x5.6x
Fri, 04 Nov 2022US$1.1tUS$206.0bUS$7.4b14x146.7x5.2x
Sun, 02 Oct 2022US$1.0tUS$206.2bUS$5.4b14.9x189.9x4.9x
Price to Earnings Ratio

189.9x


Total Market Cap: US$1.0tTotal Earnings: US$5.4bTotal Revenue: US$206.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 33.7x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.4% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.26%
Healthcare-0.038%
Biotech1.34%
Biotech1.34%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AMGN AmgenUS$279.221.6%
+US$2.4b		-10.8%PE22.7x
QURE uniQureUS$47.50235.5%
+US$2.3b		885.5%PS225.6x
MTSR MetseraUS$52.5059.9%
+US$2.1b		n/aPB12.3x
SMMT Summit TherapeuticsUS$20.5013.3%
+US$1.8b		-9.5%PB58.7x
GILD Gilead SciencesUS$113.671.3%
+US$1.7b		38.3%PE22.3x

Latest News

QURE
US$47.50
uniQure
7D
235.5%
1Y
885.5%
BIIB
US$137.67
Biogen
7D
-5.0%
1Y
-27.2%
SMMT
US$20.50
Summit Therapeutics
7D
13.3%
1Y
-9.5%
ACAD
US$21.26
ACADIA Pharmaceuticals
7D
-12.1%
1Y
38.8%
ALNY
US$458.37
Alnylam Pharmaceuticals
7D
1.5%
1Y
68.1%

RNAi Therapies Will Ensure Worldwide Market Expansion

Alnylam Pharmaceuticals’ price target was raised to $447.15 as analysts cited accelerating Amvuttra sales, positive clinical progress, robust financial execution, and increased revenue forecasts, reflecting growing confidence in the company’s commercial momentum and pipeline. Analyst Commentary Strong commercial momentum for Amvuttra, particularly in ATTR-CM, with sales trends and script data consistently exceeding expectations.
INSM
US$141.00
Insmed
7D
-2.6%
1Y
93.9%
MTSR
US$52.50
Metsera
7D
59.9%
1Y
n/a
REGN
US$576.98
Regeneron Pharmaceuticals
7D
-1.5%
1Y
-44.0%
AMGN
US$279.22
Amgen
7D
1.6%
1Y
-10.8%
UTHR
US$438.75
United Therapeutics
7D
8.7%
1Y
22.0%
VRTX
US$376.62
Vertex Pharmaceuticals
7D
-2.7%
1Y
-18.4%

Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Popularity With Investors Is Under Threat From Overpricing

Sep 19
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Popularity With Investors Is Under Threat From Overpricing
NTRA
US$163.91
Natera
7D
-8.9%
1Y
32.3%
ETNB
US$14.70
89bio
7D
81.9%
1Y
98.1%
ABBV
US$219.99
AbbVie
7D
-0.4%
1Y
15.0%
GILD
US$113.67
Gilead Sciences
7D
1.3%
1Y
38.3%
CAI
US$30.44
Caris Life Sciences
7D
-9.2%
1Y
n/a